Showing results (221-230 of 233) with videos related to

Sort By:
Pageof 24
The Medical Journal of Australia|July 22, 1985
Medulloblastoma: a clinicopathological study of 42 casesV J Ojeda, B K Armstrong, G J Cullity, et al.
Journal of the American College of Cardiology|May 1, 1992
Curative percutaneous catheter ablation using radiofrequency energy for accessory pathways in all locations: results in 100 consecutive patientsM D Lesh, G F Van Hare, D J Schamp, et al.
New Zealand Veterinary Journal|October 12, 2007
Distribution of prion protein genotypes in breeds of sheep in New ZealandM A Lee, T R Manley, B C Glass, et al.
Cell Proliferation|October 14, 2011
Epidermal regeneration by ent-16α, 17-dihydroxy-kauran-19-oic acid isolated from Siegesbeckia pubescensS-H Sung, S-H Park, S-Y Song, et al.
The American Journal of Physiology|February 1, 1997
Regulation of bFGF expression and ANG II secretion in cardiac myocytes and microvascular endothelial cellsT A Fischer, D Ungureanu-Longrois, K Singh, et al.
British Journal of Haematology|October 16, 1999
Distinct patterns of apoptosis in association with modulation of CD44 induced by thrombopoietin and granulocyte-colony stimulating factor during ex vivo expansion of human cord blood CD34+ cellsJ Y Seoh, S Y Woo, S A Im, et al.
Stem Cells (Dayton, Ohio)|August 3, 2000
Mobilization kinetics of CD34(+) cells in association with modulation of CD44 and CD31 expression during continuous intravenous administration of G-CSF in normal donorsS Lee, S A Im, E S Yoo, et al.
Science (New York, N.Y.)|October 17, 2009
Direct observations of interstellar H, He, and O by the Interstellar Boundary ExplorerE Möbius, P Bochsler, M Bzowski, et al.
Oncogene|August 11, 2015
Wnt addiction of genetically defined cancers reversed by PORCN inhibitionB Madan, Z Ke, N Harmston, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2019
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trialS T Kim, J H Kang, J Lee, et al.
Pageof 24